Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 7/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 7/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 6/20 | 0.63 |
| ▸ | CSK | P41240 | 4/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.63 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | LYN | P07948 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.62 |
| ▸ | ABL2 | P42684 | 2/20 | 0.62 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.62 |
| ▸ | FES | P07332 | 1/20 | 0.61 |
| ▸ | FER | P16591 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071823 | 0.85 | MAPK14 (0.55) | MAPK14MAP3K7MAP4K2MAP3K20EGFR | |
| SCHEMBL1135032 | 0.84 | RAF1 (0.57) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL14011570 | 0.83 | NR2C2 (0.59) | MAPK14MAP3K7MAP4K2MAP3K20FES | |
| SCHEMBL13040045 | 0.81 | RAF1 (0.46) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL13708167 | 0.79 | ATM (0.69) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL5819608 | 0.78 | MAP4K2 (0.62) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2285546 | 0.78 | DDR1 (0.71) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL29496497 | 0.78 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284678 | 0.78 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK | |
| SCHEMBL2284669 | 0.78 | MAPK14 (0.83) | MAPK14MAP3K7MAP4K2MAP3K20CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027123-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-02-23 | — | — | EP | claimed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | claimed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | claimed |
| EP-2027123-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | claimed |
| EP-2027123-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-02-23 | — | — | EP | disclosed |
| EP-2027123-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-02-23 | — | — | EP | disclosed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | disclosed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | disclosed |
| US-7846923-B2 | Compounds and compositions as protein kinase inhbitors | IRM LLC (BM) | 2010-12-07 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| EP-2027123-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | BMX, FYN, FRK | MAPK14 267/4885MAP3K7 113/4885MAP4K2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.